OpGen (NASDAQ: OPGN) stock is up 611% so far this morning premarket. This is not, we suggest, a sensible change in the OPGN stock price. In fact we think - in the absence of any other information - that this is a wild speculation. And as happens with wild speculations we think it will fade.
The thing that needs to be solved is this:

OpGen stock price from Google Finance
We cannot see any news out there which does explain it. So, we’ve got to construct an explanation for this price change. Construct that explanation as best we can.
So, start with the business line: “OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen,”. OK, we’ve a microcap - $3 million market cap - pharma developer. One that, just recently, folk were worrying would go bust. “HC Wainwright has downgraded OpGen to neutral amid concerns the company may file for bankruptcy.
The investment bank noted that OpGen revealed last week in its Q2 earnings report that it only had enough cash to fund operations to September and has substantial doubt that it can continue as a going concern. The company said it was looking at various strategic alternatives, including filing for bankruptcy under US and applicable foreign laws.”
Not a hugely attractive proposition therefore. But we’ve also just had Tempest Therapeutics. “Tempest Therapeutics (NASDAQ: TPST) stock is up 3,800% on the full day. TPST stock has reacted to the company’s announcement that it’s drug for a certain type of liver cancer seems to actually work. OK, we might think that 3,800% is rather too much for just that announcement - this isn’t FDA approval and all that as yet. Just early stage test results. The explanation for the vast percentage rise is that the starting market capitalisation was around the $3 million mark. So the value add here is around $100 million and yes, a working liver cancer drug might well be worth that much and more.”
Which is where we think the wild speculation is coming in. At least so far our opinion is that this is just a momentum trade. Based on the idea that “one $3 mil small cap pharma company jumped, therefore another will”. Given the very shaky basis of this logic we’d expect OPGN stock to retreat again.
Of course, if further information comes to light we’ll revise our opinion but that’s where we’re at right now.



